Monte Rosa Therapeutics I... (GLUE)
5.55
-0.11 (-1.94%)
At close: Jan 14, 2025, 3:59 PM
5.67
2.16%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 5.24 |
| Market Cap | 340.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.78 |
| PE Ratio (ttm) | -3.12 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 8.36 |
| Volume | 881,802 |
| Avg. Volume (20D) | 2,842,837 |
| Open | 5.73 |
| Previous Close | 5.66 |
| Day's Range | 5.49 - 5.97 |
| 52-Week Range | 3.21 - 12.40 |
| Beta | undefined |
About GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 24, 2021
Employees 133
Stock Exchange NASDAQ
Ticker Symbol GLUE
Website https://www.monterosatx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 98.20% from the latest price.
Buy 66.67%
Hold 33.33%
Sell 0.00%
Next Earnings Release
Monte Rosa Therapeutics Inc. is scheduled to release its earnings on Mar 13, 2025,
before market opens.
Analysts project revenue of $3.05M, reflecting a n/a YoY growth and earnings per share of -0.49, making a -15.52% decrease YoY.
Analysts project revenue of $3.05M, reflecting a n/a YoY growth and earnings per share of -0.49, making a -15.52% decrease YoY.
2 months ago ·
Source
+93.87%
Monte Rosa Therapeutics shares are trading higher ...
Unlock content with
Pro Subscription
